Advertisement
Person › Details
Yemi Onakunle (Selexis S.A.)
Onakunle, Yemi (JSR Corp 202001– promoted to CBO of Selexis joined 2012 before Diosynth RTP Inc + Lonza)
Organisation | Selexis S.A. | |
Group | JSR Corporation (Group) | |
Product | SUREtechnology Platform™ (Selexis) | |
Product 2 | CHO cell line | |
Record changed: 2021-03-19 |
Advertisement
More documents for Yemi Onakunle
- [1] Selexis S.A.. (3/18/21). "Press Release: SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program". Geneva....
- [2] Selexis S.A.. (1/9/20). "Press Release: Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer". Geneva....
- [3] Selexis S.A.. (1/9/19). "Press Release: Selexis Expands Strategic Immuno-Oncology Alliance with Agenus". Geneva....
- [4] Selexis S.A.. (12/17/18). "Press Release: TeneoBio and Selexis Enter Second Services Agreement to Develop Research Cell Banks". Geneva & Menlo Park, CA....
- [5] Selexis S.A.. (3/7/18). "Press Release: Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics". Geneva....
- [6] Selexis S.A.. (2/26/18). "Press Release: Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates". Geneva....
- [7] Selexis S.A.. (6/27/17). "Press Release: Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins". Geneva....
- [8] Selexis S.A.. (6/12/17). "Press Release: Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer". Geneva & Menlo Park, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top